Tag : PreP

CONFERENCE UPDATE

Zero HIV acquisition and high persistence with CAB LA as PrEP: 12-month results from the PILLAR trial
In 2022, men who have sex with men (MSM) and transgender men (TGM) accounted for 67% and <1% of new HIV diagnoses in the United States, respectively. Additionally, an estimated 15% of MSM and 3% of TGM were living with HIV. Long-acting cabotegravir (CAB LA), administered every two mo